Introduction and AimHead and neck cancer patients (HNCP) often require enteral nutritional support during chemoradiotherapy (CRT) possibly using a percutaneous endoscopic gastrostomy (PEG). Patients achieving complete oncological response and successfully resuming normal oral intake, will be scheduled for the removal of PEG post-treatment. We aim to evaluate the feasibility and safety of PEG tube removal with immediate discharge. MethodsProspective, observational, unicentric study, including all HNCP scheduled for PEG removal from October 2020 to February 2022. HNCP in remission had PEG removal with discharge after 30minutes and re-beginning cold liquid diet after 3hours. Additional therapy with omeprazole 40mg bid orally for 4 weeks was prescribed. Patients were scheduled for re-evaluation appointment after 1 month. ResultsDuring the study period, 120 HNCP scheduled for PEG removal were enrolled, with an adverse events rate of 6,7%, including seven (5.8%) persistent gastrocutaneous fistulas (GCF) and one (0.8%) parastomal hernia. 6/7 GCF solved with medical therapy alone (additional 4 weeks of PPI),1/7 required endoscopic therapy and the parastomal hernia was referred for surgery. There was no association between adverse events and patient age (p 0,343), tumor location (p=0,305) or stage (p=0,605), diabetes mellitus diagnosis (p=0,813), smoking habits (p=0,274), PEG duration (p=0,645), caliber (p=0,587) or previous PEG infections (p=0,659). ConclusionPEG removal with immediate discharge is safe, has low rate of adverse events that mostly resolve with medical therapy.